This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Contraindications to insertion of etonogestrel contraceptive implant

Authoring team

  • Consent not given.
  • Individuals under 16 years of age and assessed as not competent using Fraser Guidelines.
  • Individuals 16 years of age and over and assessed as lacking capacity to consent.
  • Known hypersensitivity to the active ingredient or to any constituent of the product - see Summary of Product Characteristics (SPC)
  • Unexplained vaginal bleeding (suspicious of serious condition) before evaluation
  • Acute porphyria

Cardiovascular Disease

  • Current or past history of ischaemic heart disease, vascular disease, stroke or transient ischaemic first attack only if these events first occurred during use of the etonogestrel implant.

Cancers

  • Current or past history of breast cancer.

Gastro-intestinal conditions

  • Severe decompensated cirrhosis.
  • Benign liver tumour (hepatocellular adenoma).
  • Malignant liver tumour (hepatocellular carcinoma).

Interacting medicines

  • Individuals using enzyme-inducing drugs/herbal products or within 28 days of stopping them.

Interacting medicines other than enzyme inducers – see current British National Formulary (BNF) or individual product SPC

Reference:

  1. Patient Group Direction (PGD) (NHS Specialist Pharmacy Service). Insertion of etonogestrel (e.g. Nexplanon®) 68mg subdermal implant for contraception . (Accessed 17th March 2021)

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.